Results 161 to 170 of about 160,408 (307)
Impact of inflammatory bowel disease on perioperative complications in patients undergoing surgery for metastatic spinal tumors. [PDF]
Fan L +5 more
europepmc +1 more source
Multi‐omics–driven precision medicine
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li +20 more
wiley +1 more source
GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease. [PDF]
Dardari D.
europepmc +1 more source
Immune Checkpoint Inhibitors Induce Intestinal Epithelial Injury and a Senescence‐Like Phenotype
ICI treatment promotes the infiltration of activated immune cells into the intestinal mucosa. This inflammatory microenvironment is associated with significant epithelial injury, characterized by the disruption of the epithelial barrier, the depletion of specialized secretory cell lineages, and the induction of a premature senescence phenotype ...
Juan Wang +7 more
wiley +1 more source
Trained immunity: An unexplored component of IBD pathogenesis. [PDF]
Doulberis M +3 more
europepmc +1 more source
ABSTRACT Particulate matter (PM) is a major global health threat, linked to millions of deaths annually. Beyond inhalation, PM components reach the gastrointestinal tract through the mucociliary escalator or contaminated food and water. Among PM's organic fraction, redox‐active quinones such as 1,2‐naphthoquinone (NQ) and 9,10‐phenanthrenequinone (PQ ...
Franco Cervellati +6 more
wiley +1 more source
Climate classification, sociodemographic development, and the burden of inflammatory bowel disease in tropical countries. [PDF]
Gong S +5 more
europepmc +1 more source
TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market.
Paediatric IBD Porto group of ESPGHAN
core

